Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy.

[1]  M. Stegall,et al.  Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. , 2000, Transplantation.

[2]  I. Roberts,et al.  Banff criteria as predictors of outcome following acute renal allograft rejection. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  G A Knoll,et al.  Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials , 1999, BMJ.

[4]  M. Henry.  Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles , 1999, Clinical transplantation.

[5]  L. Paul.  Immunosuppressive drug-induced toxicities compromising the half-life of renal allografts , 1998 .

[6]  A. Matas.  Acute rejection is a major risk factor for chronic rejection. , 1998, Transplantation proceedings.

[7]  P. Rebulla,et al.  Effect of HLA matching on cadaver kidney survival in the North Italy Transplant program. , 1998, Transplantation proceedings.

[8]  P. Keown,et al.  Cyclosporine: the principal immunosuppressant for renal transplantation. , 1998, Transplantation proceedings.

[9]  R. Moore,et al.  Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. , 1998, Transplantation proceedings.

[10]  M. Cavaillé‐Coll,et al.  Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. , 1998, Transplantation.

[11]  S. Swan,et al.  Predictive performance of renal function estimate equations in renal allografts. , 2003, British journal of clinical pharmacology.

[12]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[13]  Y. Vanrenterghem,et al.  Chronic renal allograft function under cyclosporin treatment. Leuven Collaborative Group for Transplantation. , 1996, Transplantation proceedings.

[14]  H. Bismuth.  Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. , 1995, Transplantation proceedings.

[15]  B. Kasiske,et al.  The variable nature of chronic declines in renal allograft function. , 1991, Transplantation.